A feasibility study of modified docetaxel, cisplatin, and capecitabine for advanced gastric cancer followed by gastrectomy.
Yao LiangOsamu MaedaKazushi MiyataChie TanakaMitsuro KandaDai ShimizuMasahide FukayaMasahiko KoikeYasuhiro KoderaYuichi AndoPublished in: Asia-Pacific journal of clinical oncology (2023)
mDCX seems to be feasible and may be helpful as neoadjuvant chemotherapy for patients at high risk of recurrence or as chemotherapy for patients who are likely to undergo conversion surgery.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- rectal cancer
- end stage renal disease
- phase ii study
- radiation therapy
- lymph node
- sentinel lymph node
- ejection fraction
- newly diagnosed
- minimally invasive
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- coronary artery bypass
- clinical trial
- patient reported outcomes
- early stage
- acute coronary syndrome
- atrial fibrillation